Retatrutide
Also known as: Triple agonist, GIP/GLP-1/Glucagon agonist
Investigational weekly medicine that acts on GIP, GLP-1 and glucagon receptors. It is not FDA-approved and is not available by prescription.
Evidence
Emerging
FDA status
Not FDA-approved
Source
Synthetic triple receptor agonist
Overview
Investigational weekly medicine that acts on GIP, GLP-1 and glucagon receptors. It is not FDA-approved and is not available by prescription.
Mechanism of Action
Tri-agonist activating GIP, GLP-1, and glucagon receptors simultaneously, enhances insulin secretion and suppresses appetite (GIP/GLP-1), increases energy expenditure and fat oxidation (glucagon), studied for weight, blood sugar and liver fat.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Weight loss in phase 2 and phase 3 trials
- Increased energy expenditure
- Enhanced fat oxidation
- Appetite suppression
- Improved glycemic control
- Liver fat (trials)
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. Retatrutide isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.
Research & Evidence
Phase 2 trial (NEJM 2023); phase 3 TRIUMPH trials reported in 2026
A 2023 phase 2 trial reported large weight loss at 48 weeks, and Eli Lilly reported positive phase 3 results in 2026. As of October 2026 it is not FDA-approved; Lilly has said it plans to file for approval in 2027. Products sold online as retatrutide are not the studied medicine.
Safety Information
Potential Side Effects
- •Nausea
- •Diarrhea
- •Vomiting
- •Constipation
Contraindications
- Under investigation
- Likely similar to GLP-1 agonists
Interactions
- ⚠Under investigation
Quick Facts
Related Peptides
AOD-9604
Growth hormone fragment that promotes fat loss through lipolysis without affecting IGF-1 or glucose.
Semaglutide
Weekly GLP-1 receptor agonist, FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management and other uses.
Tirzepatide
Weekly GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for weight management and obstructive sleep apnea.